Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598 for the treatment of chronic hepat

[Guest guest]

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=1790321 & contentty\

pe=sentryarticle & channelID=31

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

PR Newswire Europe (inc. UK Disclose) - Jun. 02, 2008

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.

announced today the initiation of dosing in a Phase I clinical trial of ANA598,

an investigational oral non-nucleoside polymerase inhibitor for the treatment of

chronic hepatitis C virus (HCV) infection. The objectives of this trial are to

assess safety, tolerability, and pharmacokinetics following ascending single

oral doses of ANA598 in healthy volunteers. Approximately 40 healthy subjects

will participate in the study, which is being conducted in the United States.

Following successful completion of the healthy volunteer study, Anadys plans to

begin a Phase Ib study of ANA598 in HCV-infected patients in the third quarter

of 2008.

" Based on its very favorable preclinical profile, including potency,

pharmacokinetics, and tolerability, we believe ANA598 has the potential to

become an important component of future combination therapy for patients with

HCV infection, " said Freddo, M.D., Anadys' Chief Medical Officer. " We are

excited about initiating this clinical program and look forward to future trials

of ANA598 in HCV patients, first as a single agent and then in subsequent

combination studies. We expect the full benefit of direct antivirals to be

demonstrated when studied as components of novel combination regimens

incorporating multiple anti-HCV agents. "

Steve Worland, Ph.D., Anadys' President and CEO commented, " This is a

significant milestone for Anadys. ANA598 is the second internally discovered

compound that we've moved into clinical studies this year. With the commencement

of dosing in a Phase I clinical trial for ANA773 in cancer patients in February

and this study of ANA598 underway, Anadys is now focused on achieving important

clinical milestones in both programs. "

About ANA598

ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b

NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50

values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598

has been well-tolerated in all preclinical studies, including 28-day GLP

toxicology studies, and was selected as a development candidate in June 2007.

Clinical Need and Market Opportunity in HCV Infection

Chronic hepatitis C virus (HCV) infection is a serious public health concern

affecting approximately 2.7 million people in the United States and

approximately 170 million people worldwide. HCV causes inflammation of the

liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately,

liver failure. Cirrhosis of the liver resulting from chronic HCV infection is

the leading indication for liver transplantation in the U.S. Due to the

asymptomatic nature of HCV infection, it often goes undetected for up to 20

years following initial infection. Each year, 8,000 to 10,000 people in the U.S.

die from complications of HCV.

The current standard of care is a combination of pegylated interferon and

ribavirin. Inadequate response rates, in particular for patients infected with

genotype 1 HCV, along with significant side effects of approved therapy, support

the medical need for improved treatment options. It is estimated that fewer than

5% of people with chronic HCV infection living in the U.S. are under treatment

today. The majority of infected individuals are unaware of their infection

status and the large majority of individuals who know their status do not

currently receive drug therapy. There is also a growing number of individuals

who have failed interferon-based regimens who may be successfully treated with

combinations of two or more direct antivirals. It is expected that the next

generation of therapies for treatment of HCV will include small molecules, such

as ANA598, that act directly upon specific viral enzymes to inhibit viral

replication. These direct antivirals are expected to improve overall therapy by

increasing cure rates and improving tolerability and convenience of treatment.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company

dedicated to improving patient care by developing novel medicines in the areas

of hepatitis C and oncology. The Company is developing ANA598, a non-nucleoside

polymerase inhibitor for the treatment of chronic hepatitis C and ANA773, an

oral TLR7 agonist prodrug for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature

constitute " forward-looking statements. " Such statements include, but are not

limited to, references to (i) the planned trial design of the ANA598 healthy

volunteer study; (ii) Anadys' expectation to begin a Phase Ib study of ANA598 in

the third quarter of 2008; (iii) Anadys' belief that ANA598 has the potential to

become an important component of future combination therapy for patients with

HCV infection and that the full benefit of direct antivirals will be

demonstrated when studied as components of novel combination regimens

incorporating multiple anti-HCV agents; (iv) Anadys' ability to achieve

important clinical milestones in the ANA598 and ANA773 programs; and (v)

expectations regarding the evolution of the market for HCV therapies. Such

forward-looking statements involve known and unknown risks, uncertainties and

other factors, which may cause Anadys' actual results to be materially different

from historical results or from any results expressed or implied by such

forward-looking statements. For example, the results of preclinical studies may

not be predictive of future results, and Anadys cannot provide any assurances

that ANA598 and ANA773 will not have unforeseen safety issues, will have

favorable results in future clinical trials or will receive regulatory approval.

In addition, Anadys' results may be affected by risks related to competition

from other biotechnology and pharmaceutical companies, its effectiveness at

managing its financial resources, its ability to successfully develop and market

products, difficulties or delays in its preclinical studies or clinical trials,

difficulties or delays in manufacturing its clinical trials materials, the scope

and validity of patent protection for its products, regulatory developments

involving future products and its ability to obtain additional funding to

support its operations. Risk factors that may cause actual results to differ are

more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the

year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended March

31, 2008. All forward-looking statements are qualified in their entirety by this

cautionary statement. Anadys is providing this information as of this date and

does not undertake any obligation to update any forward-looking statements

contained in this document as a result of new information, future events or

otherwise.

Anadys Pharmaceuticals, Inc.

CONTACT: Investors, T. Glover, SVP, Operations & CFO of Anadys

Pharmaceuticals, Inc., +1-858-530-3763, jglover@...; or media,

Ian Stone, ian.stone@..., or Schull,

david.schull@..., both of Russo Partners, LLC,

+1-619-814-3510, for Anadys Pharmaceuticals, Inc.

Web site: http://www.anadyspharma.com/

_________________________________________________________________

It’s easy to add contacts from Facebook and other social sites through Windows

Live™ Messenger. Learn how.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_LearnHow

[Guest guest]

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=1790321 & contentty\

pe=sentryarticle & channelID=31

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

PR Newswire Europe (inc. UK Disclose) - Jun. 02, 2008

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.

announced today the initiation of dosing in a Phase I clinical trial of ANA598,

an investigational oral non-nucleoside polymerase inhibitor for the treatment of

chronic hepatitis C virus (HCV) infection. The objectives of this trial are to

assess safety, tolerability, and pharmacokinetics following ascending single

oral doses of ANA598 in healthy volunteers. Approximately 40 healthy subjects

will participate in the study, which is being conducted in the United States.

Following successful completion of the healthy volunteer study, Anadys plans to

begin a Phase Ib study of ANA598 in HCV-infected patients in the third quarter

of 2008.

" Based on its very favorable preclinical profile, including potency,

pharmacokinetics, and tolerability, we believe ANA598 has the potential to

become an important component of future combination therapy for patients with

HCV infection, " said Freddo, M.D., Anadys' Chief Medical Officer. " We are

excited about initiating this clinical program and look forward to future trials

of ANA598 in HCV patients, first as a single agent and then in subsequent

combination studies. We expect the full benefit of direct antivirals to be

demonstrated when studied as components of novel combination regimens

incorporating multiple anti-HCV agents. "

Steve Worland, Ph.D., Anadys' President and CEO commented, " This is a

significant milestone for Anadys. ANA598 is the second internally discovered

compound that we've moved into clinical studies this year. With the commencement

of dosing in a Phase I clinical trial for ANA773 in cancer patients in February

and this study of ANA598 underway, Anadys is now focused on achieving important

clinical milestones in both programs. "

About ANA598

ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b

NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50

values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598

has been well-tolerated in all preclinical studies, including 28-day GLP

toxicology studies, and was selected as a development candidate in June 2007.

Clinical Need and Market Opportunity in HCV Infection

Chronic hepatitis C virus (HCV) infection is a serious public health concern

affecting approximately 2.7 million people in the United States and

approximately 170 million people worldwide. HCV causes inflammation of the

liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately,

liver failure. Cirrhosis of the liver resulting from chronic HCV infection is

the leading indication for liver transplantation in the U.S. Due to the

asymptomatic nature of HCV infection, it often goes undetected for up to 20

years following initial infection. Each year, 8,000 to 10,000 people in the U.S.

die from complications of HCV.

The current standard of care is a combination of pegylated interferon and

ribavirin. Inadequate response rates, in particular for patients infected with

genotype 1 HCV, along with significant side effects of approved therapy, support

the medical need for improved treatment options. It is estimated that fewer than

5% of people with chronic HCV infection living in the U.S. are under treatment

today. The majority of infected individuals are unaware of their infection

status and the large majority of individuals who know their status do not

currently receive drug therapy. There is also a growing number of individuals

who have failed interferon-based regimens who may be successfully treated with

combinations of two or more direct antivirals. It is expected that the next

generation of therapies for treatment of HCV will include small molecules, such

as ANA598, that act directly upon specific viral enzymes to inhibit viral

replication. These direct antivirals are expected to improve overall therapy by

increasing cure rates and improving tolerability and convenience of treatment.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company

dedicated to improving patient care by developing novel medicines in the areas

of hepatitis C and oncology. The Company is developing ANA598, a non-nucleoside

polymerase inhibitor for the treatment of chronic hepatitis C and ANA773, an

oral TLR7 agonist prodrug for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature

constitute " forward-looking statements. " Such statements include, but are not

limited to, references to (i) the planned trial design of the ANA598 healthy

volunteer study; (ii) Anadys' expectation to begin a Phase Ib study of ANA598 in

the third quarter of 2008; (iii) Anadys' belief that ANA598 has the potential to

become an important component of future combination therapy for patients with

HCV infection and that the full benefit of direct antivirals will be

demonstrated when studied as components of novel combination regimens

incorporating multiple anti-HCV agents; (iv) Anadys' ability to achieve

important clinical milestones in the ANA598 and ANA773 programs; and (v)

expectations regarding the evolution of the market for HCV therapies. Such

forward-looking statements involve known and unknown risks, uncertainties and

other factors, which may cause Anadys' actual results to be materially different

from historical results or from any results expressed or implied by such

forward-looking statements. For example, the results of preclinical studies may

not be predictive of future results, and Anadys cannot provide any assurances

that ANA598 and ANA773 will not have unforeseen safety issues, will have

favorable results in future clinical trials or will receive regulatory approval.

In addition, Anadys' results may be affected by risks related to competition

from other biotechnology and pharmaceutical companies, its effectiveness at

managing its financial resources, its ability to successfully develop and market

products, difficulties or delays in its preclinical studies or clinical trials,

difficulties or delays in manufacturing its clinical trials materials, the scope

and validity of patent protection for its products, regulatory developments

involving future products and its ability to obtain additional funding to

support its operations. Risk factors that may cause actual results to differ are

more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the

year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended March

31, 2008. All forward-looking statements are qualified in their entirety by this

cautionary statement. Anadys is providing this information as of this date and

does not undertake any obligation to update any forward-looking statements

contained in this document as a result of new information, future events or

otherwise.

Anadys Pharmaceuticals, Inc.

CONTACT: Investors, T. Glover, SVP, Operations & CFO of Anadys

Pharmaceuticals, Inc., +1-858-530-3763, jglover@...; or media,

Ian Stone, ian.stone@..., or Schull,

david.schull@..., both of Russo Partners, LLC,

+1-619-814-3510, for Anadys Pharmaceuticals, Inc.

Web site: http://www.anadyspharma.com/

_________________________________________________________________

It’s easy to add contacts from Facebook and other social sites through Windows

Live™ Messenger. Learn how.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_LearnHow

[Guest guest]

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=1790321 & contentty\

pe=sentryarticle & channelID=31

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

PR Newswire Europe (inc. UK Disclose) - Jun. 02, 2008

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.

announced today the initiation of dosing in a Phase I clinical trial of ANA598,

an investigational oral non-nucleoside polymerase inhibitor for the treatment of

chronic hepatitis C virus (HCV) infection. The objectives of this trial are to

assess safety, tolerability, and pharmacokinetics following ascending single

oral doses of ANA598 in healthy volunteers. Approximately 40 healthy subjects

will participate in the study, which is being conducted in the United States.

Following successful completion of the healthy volunteer study, Anadys plans to

begin a Phase Ib study of ANA598 in HCV-infected patients in the third quarter

of 2008.

" Based on its very favorable preclinical profile, including potency,

pharmacokinetics, and tolerability, we believe ANA598 has the potential to

become an important component of future combination therapy for patients with

HCV infection, " said Freddo, M.D., Anadys' Chief Medical Officer. " We are

excited about initiating this clinical program and look forward to future trials

of ANA598 in HCV patients, first as a single agent and then in subsequent

combination studies. We expect the full benefit of direct antivirals to be

demonstrated when studied as components of novel combination regimens

incorporating multiple anti-HCV agents. "

Steve Worland, Ph.D., Anadys' President and CEO commented, " This is a

significant milestone for Anadys. ANA598 is the second internally discovered

compound that we've moved into clinical studies this year. With the commencement

of dosing in a Phase I clinical trial for ANA773 in cancer patients in February

and this study of ANA598 underway, Anadys is now focused on achieving important

clinical milestones in both programs. "

About ANA598

ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b

NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50

values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598

has been well-tolerated in all preclinical studies, including 28-day GLP

toxicology studies, and was selected as a development candidate in June 2007.

Clinical Need and Market Opportunity in HCV Infection

Chronic hepatitis C virus (HCV) infection is a serious public health concern

affecting approximately 2.7 million people in the United States and

approximately 170 million people worldwide. HCV causes inflammation of the

liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately,

liver failure. Cirrhosis of the liver resulting from chronic HCV infection is

the leading indication for liver transplantation in the U.S. Due to the

asymptomatic nature of HCV infection, it often goes undetected for up to 20

years following initial infection. Each year, 8,000 to 10,000 people in the U.S.

die from complications of HCV.

The current standard of care is a combination of pegylated interferon and

ribavirin. Inadequate response rates, in particular for patients infected with

genotype 1 HCV, along with significant side effects of approved therapy, support

the medical need for improved treatment options. It is estimated that fewer than

5% of people with chronic HCV infection living in the U.S. are under treatment

today. The majority of infected individuals are unaware of their infection

status and the large majority of individuals who know their status do not

currently receive drug therapy. There is also a growing number of individuals

who have failed interferon-based regimens who may be successfully treated with

combinations of two or more direct antivirals. It is expected that the next

generation of therapies for treatment of HCV will include small molecules, such

as ANA598, that act directly upon specific viral enzymes to inhibit viral

replication. These direct antivirals are expected to improve overall therapy by

increasing cure rates and improving tolerability and convenience of treatment.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company

dedicated to improving patient care by developing novel medicines in the areas

of hepatitis C and oncology. The Company is developing ANA598, a non-nucleoside

polymerase inhibitor for the treatment of chronic hepatitis C and ANA773, an

oral TLR7 agonist prodrug for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature

constitute " forward-looking statements. " Such statements include, but are not

limited to, references to (i) the planned trial design of the ANA598 healthy

volunteer study; (ii) Anadys' expectation to begin a Phase Ib study of ANA598 in

the third quarter of 2008; (iii) Anadys' belief that ANA598 has the potential to

become an important component of future combination therapy for patients with

HCV infection and that the full benefit of direct antivirals will be

demonstrated when studied as components of novel combination regimens

incorporating multiple anti-HCV agents; (iv) Anadys' ability to achieve

important clinical milestones in the ANA598 and ANA773 programs; and (v)

expectations regarding the evolution of the market for HCV therapies. Such

forward-looking statements involve known and unknown risks, uncertainties and

other factors, which may cause Anadys' actual results to be materially different

from historical results or from any results expressed or implied by such

forward-looking statements. For example, the results of preclinical studies may

not be predictive of future results, and Anadys cannot provide any assurances

that ANA598 and ANA773 will not have unforeseen safety issues, will have

favorable results in future clinical trials or will receive regulatory approval.

In addition, Anadys' results may be affected by risks related to competition

from other biotechnology and pharmaceutical companies, its effectiveness at

managing its financial resources, its ability to successfully develop and market

products, difficulties or delays in its preclinical studies or clinical trials,

difficulties or delays in manufacturing its clinical trials materials, the scope

and validity of patent protection for its products, regulatory developments

involving future products and its ability to obtain additional funding to

support its operations. Risk factors that may cause actual results to differ are

more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the

year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended March

31, 2008. All forward-looking statements are qualified in their entirety by this

cautionary statement. Anadys is providing this information as of this date and

does not undertake any obligation to update any forward-looking statements

contained in this document as a result of new information, future events or

otherwise.

Anadys Pharmaceuticals, Inc.

CONTACT: Investors, T. Glover, SVP, Operations & CFO of Anadys

Pharmaceuticals, Inc., +1-858-530-3763, jglover@...; or media,

Ian Stone, ian.stone@..., or Schull,

david.schull@..., both of Russo Partners, LLC,

+1-619-814-3510, for Anadys Pharmaceuticals, Inc.

Web site: http://www.anadyspharma.com/

_________________________________________________________________

It’s easy to add contacts from Facebook and other social sites through Windows

Live™ Messenger. Learn how.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_LearnHow

[Guest guest]

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=1790321 & contentty\

pe=sentryarticle & channelID=31

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

PR Newswire Europe (inc. UK Disclose) - Jun. 02, 2008

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.

announced today the initiation of dosing in a Phase I clinical trial of ANA598,

an investigational oral non-nucleoside polymerase inhibitor for the treatment of

chronic hepatitis C virus (HCV) infection. The objectives of this trial are to

assess safety, tolerability, and pharmacokinetics following ascending single

oral doses of ANA598 in healthy volunteers. Approximately 40 healthy subjects

will participate in the study, which is being conducted in the United States.

Following successful completion of the healthy volunteer study, Anadys plans to

begin a Phase Ib study of ANA598 in HCV-infected patients in the third quarter

of 2008.

" Based on its very favorable preclinical profile, including potency,

pharmacokinetics, and tolerability, we believe ANA598 has the potential to

become an important component of future combination therapy for patients with

HCV infection, " said Freddo, M.D., Anadys' Chief Medical Officer. " We are

excited about initiating this clinical program and look forward to future trials

of ANA598 in HCV patients, first as a single agent and then in subsequent

combination studies. We expect the full benefit of direct antivirals to be

demonstrated when studied as components of novel combination regimens

incorporating multiple anti-HCV agents. "

Steve Worland, Ph.D., Anadys' President and CEO commented, " This is a

significant milestone for Anadys. ANA598 is the second internally discovered

compound that we've moved into clinical studies this year. With the commencement

of dosing in a Phase I clinical trial for ANA773 in cancer patients in February

and this study of ANA598 underway, Anadys is now focused on achieving important

clinical milestones in both programs. "

About ANA598

ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b

NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50

values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598

has been well-tolerated in all preclinical studies, including 28-day GLP

toxicology studies, and was selected as a development candidate in June 2007.

Clinical Need and Market Opportunity in HCV Infection

Chronic hepatitis C virus (HCV) infection is a serious public health concern

affecting approximately 2.7 million people in the United States and

approximately 170 million people worldwide. HCV causes inflammation of the

liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately,

liver failure. Cirrhosis of the liver resulting from chronic HCV infection is

the leading indication for liver transplantation in the U.S. Due to the

asymptomatic nature of HCV infection, it often goes undetected for up to 20

years following initial infection. Each year, 8,000 to 10,000 people in the U.S.

die from complications of HCV.

The current standard of care is a combination of pegylated interferon and

ribavirin. Inadequate response rates, in particular for patients infected with

genotype 1 HCV, along with significant side effects of approved therapy, support

the medical need for improved treatment options. It is estimated that fewer than

5% of people with chronic HCV infection living in the U.S. are under treatment

today. The majority of infected individuals are unaware of their infection

status and the large majority of individuals who know their status do not

currently receive drug therapy. There is also a growing number of individuals

who have failed interferon-based regimens who may be successfully treated with

combinations of two or more direct antivirals. It is expected that the next

generation of therapies for treatment of HCV will include small molecules, such

as ANA598, that act directly upon specific viral enzymes to inhibit viral

replication. These direct antivirals are expected to improve overall therapy by

increasing cure rates and improving tolerability and convenience of treatment.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company

dedicated to improving patient care by developing novel medicines in the areas

of hepatitis C and oncology. The Company is developing ANA598, a non-nucleoside

polymerase inhibitor for the treatment of chronic hepatitis C and ANA773, an

oral TLR7 agonist prodrug for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature

constitute " forward-looking statements. " Such statements include, but are not

limited to, references to (i) the planned trial design of the ANA598 healthy

volunteer study; (ii) Anadys' expectation to begin a Phase Ib study of ANA598 in

the third quarter of 2008; (iii) Anadys' belief that ANA598 has the potential to

become an important component of future combination therapy for patients with

HCV infection and that the full benefit of direct antivirals will be

demonstrated when studied as components of novel combination regimens

incorporating multiple anti-HCV agents; (iv) Anadys' ability to achieve

important clinical milestones in the ANA598 and ANA773 programs; and (v)

expectations regarding the evolution of the market for HCV therapies. Such

forward-looking statements involve known and unknown risks, uncertainties and

other factors, which may cause Anadys' actual results to be materially different

from historical results or from any results expressed or implied by such

forward-looking statements. For example, the results of preclinical studies may

not be predictive of future results, and Anadys cannot provide any assurances

that ANA598 and ANA773 will not have unforeseen safety issues, will have

favorable results in future clinical trials or will receive regulatory approval.

In addition, Anadys' results may be affected by risks related to competition

from other biotechnology and pharmaceutical companies, its effectiveness at

managing its financial resources, its ability to successfully develop and market

products, difficulties or delays in its preclinical studies or clinical trials,

difficulties or delays in manufacturing its clinical trials materials, the scope

and validity of patent protection for its products, regulatory developments

involving future products and its ability to obtain additional funding to

support its operations. Risk factors that may cause actual results to differ are

more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the

year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended March

31, 2008. All forward-looking statements are qualified in their entirety by this

cautionary statement. Anadys is providing this information as of this date and

does not undertake any obligation to update any forward-looking statements

contained in this document as a result of new information, future events or

otherwise.

Anadys Pharmaceuticals, Inc.

CONTACT: Investors, T. Glover, SVP, Operations & CFO of Anadys

Pharmaceuticals, Inc., +1-858-530-3763, jglover@...; or media,

Ian Stone, ian.stone@..., or Schull,

david.schull@..., both of Russo Partners, LLC,

+1-619-814-3510, for Anadys Pharmaceuticals, Inc.

Web site: http://www.anadyspharma.com/

_________________________________________________________________

It’s easy to add contacts from Facebook and other social sites through Windows

Live™ Messenger. Learn how.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_LearnHow